Victory Capital Management
DNTH icon

Victory Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Victory Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Buy
15,662
+872
+6% +$50.5K ﹤0.01% 1731
2025
Q4 		$609K Buy
+14,790
New +$573K ﹤0.01% 1985
2020
Q2 		– Sell
-443
Closed -$44K – 2720
2020
Q1 		$44K Buy
+443
New +$82.1K ﹤0.01% 2824
2019
Q4 		– Sell
-187
Closed -$31K – 2811
2019
Q3 		$31K Buy
+187
New +$35.5K ﹤0.01% 2890

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Victory Capital Management's DNTH Position: Q1 2026 in Review

Victory Capital Management increased its Dianthus Therapeutics (DNTH) stake by 5.9% in Q1 2026, buying an estimated $50.5K and bringing the position to 15,662 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1731.

Victory Capital Management first reported a position in DNTH in Q3 2019 and has held it in 4 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Victory Capital Management held 15,662 shares of Dianthus Therapeutics worth $1.31M as of Q1 2026.
  • Victory Capital Management bought 872 Dianthus Therapeutics shares in Q1 2026, an estimated $50.5K.
  • Dianthus Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1731 holding.
  • Victory Capital Management first reported a position in Dianthus Therapeutics in Q3 2019 and has held it in 4 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.